Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Merck $5 Billion Notes Offering
Davis Polk advised the representatives of the underwriters in connection with the offering of $5.0 billion aggregate…
Davis Polk Advises CStone Pharmaceuticals on Its HK$2.24 Billion (US$285.05 Million) Initial Public Offering
Davis Polk advised CStone Pharmaceuticals in connection with its initial public offering and listing on the Hong Kong Stock…
Davis Polk Advises Roche on Its Acquisition of Spark Therapeutics
Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction,…
Eli Lilly $4.5 Billion Notes Offering
Davis Polk advised the joint book-running managers in connection with a $4.5 billion registered offering by Eli Lilly and…
Pernix Enters into an Agreement for the Sale of Substantially All of Its Assets Subject to a Competitive Bidding Process and Files for Chapter 11
Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the…
Sienna Biopharmaceuticals, Inc. $20 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by…
Alector, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of…
Aeglea BioTherapeutics, Inc. Common Stock and Pre-Funded Warrants Offering
Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre…
Revance Therapeutics, Inc. $115 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $115…
Stemline Therapeutics, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…